XBiotech Inc. (NASDAQ:XBIT) and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aridis Pharmaceuticals Inc.||2.16M||32.34||23.74M||-2.98||0.00|
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 hightlights the return on assets, net margins and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|Aridis Pharmaceuticals Inc.||-1,099.07%||54.6%||-91.5%|
XBiotech Inc. has a Current Ratio of 9.3 and a Quick Ratio of 9.3. Competitively, Aridis Pharmaceuticals Inc.’s Current Ratio is 5 and has 5 Quick Ratio. XBiotech Inc.’s better ability to pay short and long-term obligations than Aridis Pharmaceuticals Inc.
Institutional & Insider Ownership
The shares of both XBiotech Inc. and Aridis Pharmaceuticals Inc. are owned by institutional investors at 4.3% and 0.7% respectively. Insiders held 9.5% of XBiotech Inc. shares. On the other hand, insiders held about 17.8% of Aridis Pharmaceuticals Inc.’s shares.
Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Aridis Pharmaceuticals Inc.||-25%||-34.84%||-41.67%||0%||0%||-38.85%|
For the past year XBiotech Inc. has 5.08% stronger performance while Aridis Pharmaceuticals Inc. has -38.85% weaker performance.
XBiotech Inc. beats on 6 of the 9 factors Aridis Pharmaceuticals Inc.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.